Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pacific Biosciences of CaliforniaPACB -3.38%59 3-Year EBITDA Growth Rate is 26.00% as of Jun. 2026, which is 90% above its 10-year median of 13.70. GuruFocus rates PACB with a GF Score™ of 59/100 and a GF Value™ of $1.49 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 692 Medical Devices & Instruments companies, Pacific Biosciences of California ranks better than 73.41% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 26.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Pacific Biosciences of California was 75.60% per year. The lowest was -158.60% per year. And the median was 13.70% per year.
Pacific Biosciences of California (NAS:PACB) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Pacific Biosciences of California 3-Year EBITDA Growth Rate Related Terms
PACB vs DCTH, CLPT, SI: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Pacific Biosciences of California's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacific Biosciences of California 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Pacific Biosciences of California's 3-Year EBITDA Growth Rate falls into.
Pacific Biosciences of California 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 26.00% mean?
Pacific Biosciences of California (PACB) has a 3-Year EBITDA Growth Rate of 26.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Pacific Biosciences of California and its competitors. This is 90% above median its historical median of 13.70. According to the industry distribution chart, Pacific Biosciences of California ranks #184 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 26.6%.
Is Pacific Biosciences of California's 3-Year EBITDA Growth Rate too high?
Pacific Biosciences of California's current 3-Year EBITDA Growth Rate of 26.00% is 90% above median its 10-year median of 13.70. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. Pacific Biosciences of California's value of 26.00% is 217.1% above this industry median. Based on the distribution chart, Pacific Biosciences of California ranks #184 out of 692 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Pacific Biosciences of California has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pacific Biosciences of California's 3-Year EBITDA Growth Rate compare to DCTH and CLPT?
According to the Medical Devices & Instruments industry distribution chart, Pacific Biosciences of California ranks #184 out of 692 companies for 3-Year EBITDA Growth Rate. This puts Pacific Biosciences of California in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.20. Pacific Biosciences of California's value of 26.00% is 217.1% above this benchmark. While the company's 10-year median is 13.70 vs. the industry median of 8.20, Pacific Biosciences of California has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacific Biosciences of California's current 3-Year EBITDA Growth Rate of 26.00% is 217.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Pacific Biosciences of California and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacific Biosciences of California's current 3-Year EBITDA Growth Rate is 26.00%, which is 90% above median its own 10-year median of 13.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Biosciences of California stock overvalued right now?
Based on GuruFocus' analysis, Pacific Biosciences of California (PACB) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.49, compared to a current price of $1.15 — trading 23.2% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 26.00%, which is 90% above median its 10-year median of 13.70 and 217.1% above the Medical Devices & Instruments industry median of 8.20. Pacific Biosciences of California's overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Pacific Biosciences of California (PACB), the current 3-Year EBITDA Growth Rate is 26.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacific Biosciences of California (PACB) Overvalued in 2026?
Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be undervalued.
The current stock price of $1.15 is trading 23.2% below its estimated GF Value™ of $1.49.
GuruFocus considers Pacific Biosciences of California to be Modestly Undervalued.
Key valuation signals for PACB:
3-Year EBITDA Growth Rate: 26.00% (90% above median its 10-year median of 13.70)
GF Value™: $1.49 vs. price of $1.15 (23.2% below fair value)
Industry Position: 217.1% above the Medical Devices & Instruments median (#184 of 692)
No single metric tells the full story. See the PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
59GF Score
Get the complete analysis for PACB
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PACB has been successfully added to your 
